[Glucagon-like peptide-1: a cardiological perspective].
Increasing experimental evidence points to direct effects of glucagon-like peptide-1 (GLP-1) and its analogs on the heart and circulatory system, in addition to the well-established, antidiabetic actions of these agents on glucose and on the energy metabolism. These effects are primarily vasodilation, diminished heart muscle loss after myocardial infarction and a contractility increase of a weak left ventricle. A few, small patient trials appear to support the latter effect. Experimental results suggest the myocardium-saving effect following coronary occlusion and reperfusion as particularly suitable for clinical testing.
Kobenhavns Universitet, Biomedicinsk Institut, Denmark.
Mikkel
M
Elvekjaer
Thomas
T
Engstrøm
Jan Skov
JS
Jensen
Marek
M
Treiman
D002311:Cardiomyopathy, Dilated / Q000188:drug therapy; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006321:Heart / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069450:Liraglutide; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000187:drug effects / Q000378:metabolism; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use
C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide